Mark Brunswick PhD

Dr. Mark Brunswick has over 35 years of experience in Regulated Industry including over 9 years in the US FDA, Center for Biologics, Division of Monoclonal Antibodies. Most recently, Dr. Brunswick was Head of Regulatory Affairs and Quality at Sophiris Bio, a company developing a drug for benign prostatic hyperplasia and prostate cancer. Prior to that he was head of Regulatory Affairs at Arena Pharmaceuticals, a company specializing in therapies directed at G Protein receptors and led the regulatory group at Elan Pharmaceuticals concentrating on Alzheimer Disease and the pain compound, ziconotide. He obtained his Ph.D. from University College London, University of London.